Gastrointestinal cancer is a serious disease that can lead to fatality. There are two basic effectors such as UPR mediated ER stress causing malignant transformation and tumor growth and the other one is extracellular matrix (ECM) and its remodelling (angiogenic molecule) for cancer progression. Various antioxidant, anti-inflammatory, anti-viral, and immune-modulating properties of modern pharmacological agents are widely used to treat GI inflammation, hepatitis, organ fibrosis, metabolic diseases, cancers, and autoimmune diseases. The mechanism of many drugs’ action remains unknown, and the viability of the independence assumption is often not met. Therefore, investigating novel therapeutic drugs and their role on ECM and its remodelling during cancer progression and ER stress mediated cancer growth inhibition are of utmost importance in the field of drug discovery.
This Research Topic has been dedicated to investigating the cellular and molecular mechanism of GI tract diseases and cancer. The research articles will try to cover but are not limited to understanding the pathophysiological and pathogenesis in both in vitro, in vivo, and ex vivo using patient-derived tissue or patient-derived xenograft (PDX) model system of inflammatory diseases of GI tract and cancer of GI tract. Perspective articles will be aimed at providing advances and future perspectives from basic research to translational research in search of new potential drug targets to mitigate the disease phenomenon. Manuscripts further exploring the novel approaches in designing drugs to block the pathways and mechanisms of such disease conditions would be welcome. It will also give opportunities to those avenues of research that involve both commercially available drugs to novel (single/combination) drugs synthesized for management, biochemical formulation of new nanomolecular drugs and targets, as well as traditional bioactive compounds with known structure and composition. The articles should provide significant studies to shed light on the functional, biochemical and molecular interaction of drugs with cellular activities to control the disease.
The Topic Editors welcome original research articles, reviews, opinion and perspective articles including but not limited to the following themes:
• Investigations on the pathophysiological mechanism of gastrointestinal inflammation leading to cancer
• Signalling pathways of gastrointestinal inflammation, cancer, and ECM remodelling
• Novel concepts and the treatment strategies of GI diseases and cancers
• Therapeutic targets on GI inflammation and cancer with respect to unfolded protein response mediated (UPR) endoplasmic reticulum (ER) stress, angiogenesis.
• Drug design and pharmacological interventions approach against inflammatory disease and cancer of GI tract.
• Research on novel single/combinatorial drug treatment and evaluation on inflammatory disease and cancer of GI tract.
Gastrointestinal cancer is a serious disease that can lead to fatality. There are two basic effectors such as UPR mediated ER stress causing malignant transformation and tumor growth and the other one is extracellular matrix (ECM) and its remodelling (angiogenic molecule) for cancer progression. Various antioxidant, anti-inflammatory, anti-viral, and immune-modulating properties of modern pharmacological agents are widely used to treat GI inflammation, hepatitis, organ fibrosis, metabolic diseases, cancers, and autoimmune diseases. The mechanism of many drugs’ action remains unknown, and the viability of the independence assumption is often not met. Therefore, investigating novel therapeutic drugs and their role on ECM and its remodelling during cancer progression and ER stress mediated cancer growth inhibition are of utmost importance in the field of drug discovery.
This Research Topic has been dedicated to investigating the cellular and molecular mechanism of GI tract diseases and cancer. The research articles will try to cover but are not limited to understanding the pathophysiological and pathogenesis in both in vitro, in vivo, and ex vivo using patient-derived tissue or patient-derived xenograft (PDX) model system of inflammatory diseases of GI tract and cancer of GI tract. Perspective articles will be aimed at providing advances and future perspectives from basic research to translational research in search of new potential drug targets to mitigate the disease phenomenon. Manuscripts further exploring the novel approaches in designing drugs to block the pathways and mechanisms of such disease conditions would be welcome. It will also give opportunities to those avenues of research that involve both commercially available drugs to novel (single/combination) drugs synthesized for management, biochemical formulation of new nanomolecular drugs and targets, as well as traditional bioactive compounds with known structure and composition. The articles should provide significant studies to shed light on the functional, biochemical and molecular interaction of drugs with cellular activities to control the disease.
The Topic Editors welcome original research articles, reviews, opinion and perspective articles including but not limited to the following themes:
• Investigations on the pathophysiological mechanism of gastrointestinal inflammation leading to cancer
• Signalling pathways of gastrointestinal inflammation, cancer, and ECM remodelling
• Novel concepts and the treatment strategies of GI diseases and cancers
• Therapeutic targets on GI inflammation and cancer with respect to unfolded protein response mediated (UPR) endoplasmic reticulum (ER) stress, angiogenesis.
• Drug design and pharmacological interventions approach against inflammatory disease and cancer of GI tract.
• Research on novel single/combinatorial drug treatment and evaluation on inflammatory disease and cancer of GI tract.
